Hunan Fangsheng Pharmaceutical Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Hunan Fangsheng Pharmaceutical Co., Ltd. was founded in June 2002 and is a high-quality, comprehensive, and research-oriented pharmaceutical and health industry group that integrates pharmaceutical industry, medical services, and big health business. It has multiple subsidiaries and was successfully listed on the Shanghai Stock Exchange on December 5, 2014, officially entering the capital market (stock code: 603998). Since its establishment, Fangsheng has rapidly risen at a steady pace of development and has grown into a benchmark enterprise in the pharmaceutical industry in Hunan Province. It has been awarded the titles of Key High tech Enterprise of the National Torch Plan, Top 100 Brand Enterprise of Chinese National Medicine, AAA Integrity Enterprise of Chinese Pharmaceutical Industry, Excellent Private Enterprise of China, National Contract abiding and Credit Valuing Enterprise, Hunan Provincial Governor Quality Award Enterprise, and the first batch of exemplary pharmaceutical enterprises in Hunan Province. Fangsheng takes "Your Health, Fangsheng's Pursuit" as its corporate mission. Since its establishment for more than 10 years, it has been continuously exploring, trying, and developing in various fields of big health, always committed to serving human health. It has constructed a "one body, two wings" strategic layout with the pharmaceutical industry as the main body and medical services and big health (health consumption, elderly care) as the two wings. In the pharmaceutical industry, with Fangsheng Pharmaceutical headquarters as the main body and subsidiary companies such as Xiangya Pharmaceutical, Hainan Boda, and Sanhua Pharmaceutical as auxiliary forces for development; At the same time, we will rapidly promote the construction of Fangsheng Lipu's international factory, create an international technology platform that can meet both FDA and NMPA requirements, and accelerate integration with the international market; In terms of the medical industry, relying on the investment targets of two industry funds established by the company, Baijun Medical and Kexin Health, to meet the growing health service needs of the people in the fields of kidney disease and cancer; In terms of health and elderly care, Xiangya Pharmaceutical's "Xiangya Xile Garden" is used as the carrier to create a elderly care lifestyle model that combines "nursing homes" and "sunshine centers", promoting the company's development and layout in the elderly care industry. Fangsheng takes "new drug research and development capabilities" as its core competitive advantage, integrates the advantages of global top new drug research and development resources, forms a high-level research and development team, and establishes a product research and development strategy that combines "traditional Chinese medicine, chemical medicine, and biological medicine". With the important characteristics of imitation, improvement, innovation, and internationalization of complex chemical drug formulations, Fangsheng continuously promotes the "1+N" model of international large research and development system, achieving integrated development in multiple technologies and fields. In the field of traditional Chinese medicine, Fangsheng has successfully developed several major brand series products, including "Xinxuean" brand cardio cerebrovascular department, "Jinbeibei" brand pediatric department, "Meiershu" brand gynecological department, and "Fangshengtang" brand orthopedic department. In the field of chemical medicine, Fangsheng is committed to focusing on the development of heavyweight drugs for the prevention and treatment of major diseases. Its subsidiary, Fangsheng Huamei, is about to complete the Phase I clinical trial of a self-developed Class 1 anticancer drug, Diantecan Sodium for Injection. Lipo in the United States has completed its preliminary research and development work on paclitaxel (albumin binding) for injection. In the field of biopharmaceuticals, the "National Engineering Research Center for Genetically Engineered Drugs" of Jida Gene has successfully passed the acceptance, and has broad prospects for future development. At present, Fangsheng has achieved the management of the entire value chain of pharmaceutical research, clinical research, consistency evaluation, production and sales in the field of new drug development. The company currently has a nationally recognized enterprise technology center and postdoctoral research workstation, undertaking major national new drug innovation technology projects and multiple provincial-level science and technology projects. It has obtained over 160 drug production approvals, nearly 20 new drug certificates, nearly 40 invention patents, and 2 international patents. Its rich product reserves provide strong support for realizing the Fangsheng strategy and meeting the health needs of the people. Fangsheng has established a professional marketing team, with a marketing network covering hospitals, chain and individual pharmacies, and clinics at all levels in various provinces and cities across the country. With excellent product quality and professional and high-quality services, Fangsheng has established its brand in the pharmaceutical field. The company fully promotes professional and academic marketing, and through diversified academic activities, together with medical institutions at all levels, helps to improve the overall medical level in China. Fangsheng has multiple production bases in Changsha, Hainan, Liaoning, Yunnan and other places, and strictly organizes production in accordance with the requirements of the new GMP and excellent performance system. It has established a comprehensive quality control and assurance system, implements quality management throughout the entire process and staff, and ensures the quality and safety of people's medication. The Fangsheng Pharmaceutical Industrial Park, located in Changsha High tech Zone, covers an area of 150 acres with a total construction area of 230000 square meters, providing strong support for the production capacity required for the company's strategic development. In the future, Fangsheng will continue to focus on the pharmaceutical industry, strengthen the core competitive advantage of new drug research and development, leverage the power of capital to drive the development of the industry, and ultimately achieve the strategic layout of the pharmaceutical industry, medical services, and health and elderly care "one body and two wings". We will create a high-quality, comprehensive, and scientific research oriented pharmaceutical and health industry carrier, achieve Fangsheng Dream, and achieve the health dream!. |
| Headquarter | Changsha |
| Establish Date | 10/13/1997 |
| Listed Code | 603998.SH |
| Listed Date | 12/5/2014 |
| Chairman | Zhou Xiaoli. |
| CEO | Zhou Xiaoli. |
| Website | www.fangsheng.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
